It was reported that the patient presented to the emergency department on (b)(6) 2022 after having dark, tarry stools since (b)(6) 2022.The patient had labs, x-rays, and electrocardiogram done upon admission.Chest x-ray was stable from their last study, and there was a small pleural effusion and no pneumothorax.Hemoglobin was stable at 13.9 g/dl and the patient was discharged with instructions to return if excessive bleeding from gastrointestinal tract was noted.
|
Manufacturer's investigation conclusion: a direct correlation between the device and the reported gastrointestinal bleeding and pleural effusion could not be conclusively determined through this evaluation.The patient remains ongoing with heartmate 3 left ventricular assist system (lvas), serial number (b)(6).No further related events have been reported at this time.The relevant sections of the device history records for (b)(6) were reviewed and showed no deviations from manufacturing or quality assurance specifications.The heartmate 3 left ventricular assist system (lvas) instructions for use (ifu) is currently available.Section 1 ¿introduction¿ of this document lists bleeding as an adverse event that may be associated with the use of heartmate 3 lvas.Additionally, section 6 ¿patient care and management¿ provides information regarding the recommended anticoagulation therapy and inr (international normalized ratio) range, as well as considerations for when there is a risk of bleeding.No further information was provided.The manufacturer is closing the file on this event.
|